110952-26-6

Basic information

• Product Name: 6-[(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalene)-6-ylcarbonyl]-2-naphthalenecarboxylic acid
• Synonyms: 6-[(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalene)-6-ylcarbonyl]-2-naphthalenecarboxylic acid;6-[(5,6,7,8-Tetrahydro-5,5,8,8-tetramethylnaphthalen)-2-ylcarbonyl]-2-naphthalenecarboxylic acid;CD-564
• CAS NO: 110952-26-6
• Molecular Formula: C26H26 O3
• Molecular Weight: 386.48
• Mol File: 110952-26-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-[(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalene)-6-ylcarbonyl]-2-naphthalenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalene)-6-ylcarbonyl]-2-naphthalenecarboxylic acid(110952-26-6)
• EPA Substance Registry System: 6-[(1,2,3,4-Tetrahydro-1,1,4,4-tetramethylnaphthalene)-6-ylcarbonyl]-2-naphthalenecarboxylic acid(110952-26-6)

Safety Data

• Hazardous Substances Data: 110952-26-6(Hazardous Substances Data)

Upstream product

• 69008-41-9 6-(Chlorocarbonyl)-2-naphthalenecarboxylic acid,methyl ester 
• 6683-46-1 1,1,4,4-Tetramethyl-1,2,3,4-tetrahydro-naphthalene 

Relevant articles and documents

Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase

Cytochrome P450 CYP26 enzymes are responsible for all-trans-retinoic acid (atRA) clearance. Inhibition of CYP26 enzymes will increase endogenous atRA concentrations and is an attractive therapeutic target. However, the selectivity and potency of the exist

PPAR receptor activator compounds for treating cutaneous disorders/afflictions

Compounds of formula (I): characteristically activators of receptors of PPAR type, are well suited for treating cutaneous disorders/afflictions, notably rosacea, intrinsic (or chronological) aging, pigmentation disorders, seborrhoeic function disorders, barrier function disorders and more particularly epidermal lipid secretion disorders, wound healing disorders, corticosteroid-induced cutaneous atrophies, or ulcers, immune system disorders, cardiovascular system conditions, and/or lipid metabolism disorders.

Bicyclic naphthalenic derivatives, a process for preparing the same and human or veterinary medicines and cosmetic compositions containing said derivatives

A bicyclic naphthalenic compound has the formula STR1 wherein A represents methylene or dimethylene, substituted or not by lower alkyl, R1, R2, R3 and R4 represent hydrogen or lower alkyl, or R1 and R3 taken together form a methylene or dimethylene bridge when A represents dimethylene, R' represents hydrogen, OH, alkoxy having 1-4 carbon atoms, acyloxy having 1-4 carbon atoms or amino, R" represents hydrogen or alkoxy having 1-4 carbon atoms, or r' and R" taken together form an oxo, methano or hydroxyimino group, R represents --CH2 OH or --COR5, R5 represents hydrogen, --OR6 or STR2 R6 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl, polyhydroxyalkyl, aryl or aralkyl optionally substituted, the residue of a sugar or STR3 p is 1, 2 or 3, and r' and r", each independently, represent hydrogen, lower alkyl, monohydroxyalkyl optionally interrupted by a heteroatom, polyhydroxyalkyl, aryl or benzyl optionally substituted, the residue of an amino acid, an aminoester or an aminated sugar, or r' and r" together form with the nitrogen atom to which they are attached, a heterocycle substituted or not, and the salts of said compounds of formula (I) or the optional isomers thereof.